$ 32.13
Key Takeaways
Risk factor
Strong trading liquidity
Profitability factor
Undervalued vs peers
About
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries....
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, overvalued on EV/EBITDA, overpriced on P/FCF.
Target Price
The average target price of ENOV is 53 and suggests 66% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
